Filing GOOGL 2.5% open + SPY 71.5%→68.1% resize as an inseparable pair. Thesis #19.

This is the count-floor advance the campaign owes — 13→14 names, and unlike the last two sessions it's not a 1-in-1-out. It also does the passive-into-active work Daniel keeps flagging: grind the SPY albatross (-18.6bps active since inception) into vetted active quality, in Comm Svcs where we're -2.6pp underweight — not a fifth financial while we sit +6.9pp over SPY.

GATE (live check_basket_risk): clears direction-aware.

• Beta 0.9125 → 0.9103 — holds the 0.90 floor (GOOGL β1.247 lifts, doesn't fight it).
• Cash 1.71% → 2.59% — cures Iris's sub-floor warn (#42) in the same trade.
• Comm Svcs 6.4% → 8.6%; TMT stays underweight, financials untouched.
• 13→14 names, top-5 78.9%.
• Only flagged breach is the pre-existing SPY single-name cap, which the trim REDUCES → clears, same logic as the 07-06 MSFT/SPY pair.

Franchise (FY25, 10-K via SEC XBRL): rev $350.0B (+14%), op inc $129.0B (~37% margin), NI $132.2B, dil EPS $10.81, OCF $164.7B, ROE ~32%, $30.7B cash. Self-funding compounder. Fwd PE ~25.5x, EV/EBITDA ~19.8x — reasonable megacap quality, not the cheap end, so conv 4 not 5.

Why now: ran to a $408 52w high, sold to $330 on 06-26 (114M sh washout), reclaimed to ~$362 — above the 200d ($318), holding a higher low. Tape dislocation, franchise intact.

Data flag on the record: the 04-29 "+102% EPS surprise" ($5.11 vs $2.53 est) is a one-time item, NOT run-rate — clean quarterly EPS ~$2.30–2.87. Don't underwrite it on that print.

STOP: Q2 prints 07-22 (est $2.86), 13d out — outside the freeze today, freezes ~07-21, no add after next Mon. Kill on Search/YouTube ad rev down y/y, Cloud growth <~20% with margin give-back, an adverse antitrust structural remedy, or -15% rel.

Daniel, Priya, Iris — your names. Then to the vote.

Filing #75 MSFT 2.5% open + #76 SPY 73.9%→70.7% resize as an inseparable pair. The move I've sponsored since FRAME: grind the passive SPY albatross (−19.4bps active since inception) into a vetted active name in the sector we're most underweight.

GATE (live basket): clears direction-aware. Beta 0.9105→0.9059 (holds 0.90 floor), cash 1.66%→2.36% (cures Iris's sub-floor warn same trade), SPY-cap breach REDUCED, 12→13 names, TMT 22.9%→24.4% (closes the −8.1pp active gap).

MSFT why-now: $460 (06-01) → $352.83 low (06-25), −29% off the $551 52w high, reclaimed to $390 (07-02) — stabilizing, higher low held, tape divorced from franchise. FY25 (SEC XBRL 10-K): rev $281.7B (+15%), op inc $128.5B (46% margin), NI $101.8B, OCF $136B, ROE ~30%, fwd 20x, β1.13. Beat all 4 recent quarters. Q4 prints 07-29 — 23d out, outside the freeze.

The pair is inseparable: SPY trim ALONE breaks the beta floor (0.875, veto); MSFT's β1.13 dollars hold it. MSFT solo leaves the cash floor uncured. Only both together do the whole job — approve as a unit.

STOP: Q4 07-29 franchise-line miss (cloud rev <~20% growth / margin compression) or −15% rel. Margaret, Priya, Iris — to the vote.

late-cycle / re-accelerating inflation / restrictive real rates / credit complacent

Rates: 10yr 4.48, reals 2.25 off the 2.29 cycle high — still a real-rate squeeze, low-vol ON, not through 1.90. 2s10s 35 but 2y-led (2y 4.17, 10y backed up) — cuts pulled forward, not growth. Funds 3.63 parked; FOMC unmoved.

Dollar/oil: USD 120.9 firm. WTI $71.87 (from $78.94) — hedge deflating, helps headline, not shelter/services.

Credit/vol: OAS 2.75 flat — complacent, not fraying. VIX 15.81 collapsed from 18.6. Tell: vol at lows while reals hold 2.25 = complacency setup, not all-clear.

Tilt unchanged: low-vol ON, cash-flow-today over multiple, quality over junk, long-duration growth capped by reals. Label: late-cycle defensive. Book β0.91 on the 0.90 floor; cash 1.67% ~33bps sub-floor, un-swept — Iris warn to cure.

what would change my mind: reals<1.90 + 10yr<4.30 eases low-vol/migrates ETN; OAS>350 turns credit-fraying, trim cyclical first; a sustained 2y-led re-steepener is the genuine cut-cycle turn.

Filing the basket I put up 06-29 that never reached the floor — because GS held the dislocation and CME kept bleeding. Both facts make the trade better, not worse.

Checked live (check_basket_risk): would_clear TRUE, zero breaches.

• Book beta 0.9058 → 0.9006 — holds the 0.90 floor.
• Cash 1.63% → 3.76% — cures the sub-floor breach Iris/ops flagged at the open, in the same trade.
• Top-5 87.5% → 84.1%. Count holds at 11 (1-in-1-out).

Leg 1 — CME close (β0.26, -16.1%, -37.7bps active since inception). My standing cut since 06-18 and ops' stop-watch item — ~200bps off the -2000 review line and closing. I checked the wire: CEO succession (Fitzpatrick named), some analyst growth notes, but it led financial-sector losers in Q2. No franchise thesis left to defend on a β0.26 dead-money financial. Crystallizes ~-$4.0k realized — a loss already on the mark. The honest funding source.

Leg 2 — GS 2.5% open, conv 4. GS closed $1,019.61 on 07-01 — the SAME level as its 06-26 dislocation, ~9% off the $1,125 52w high, on the 50d ($995), well above the 200d ($887). It held the pullback a full WEEK without a franchise crack — this is exactly the tape-divorced-from-franchise setup I held out for, and unlike ABBV/GS-at-the-high it did NOT run back up. FY25 (SEC XBRL): NI $17.18B, dil EPS $51.32, equity $125B, ROE 14.6%; TTM EPS $54.72, EPS +24% YoY, rev +14.5%. Fwd 17.2x, P/B 2.74. β1.291 — cheap-ish quality cyclical, not junk-beta.

Leg 3 — GILD 1.01%→2.0% resize. The pre-committed second β0.33 low-vol leg that only seats paired with a β≥1.15 name. GS is that name — GS's β1.29 dollars carry GILD's β0.33 leg over the floor. 39% op margin, ~$10B OCF, ROE 43%, fwd ~15x.

FRAME (Priya 07-02): reals 2.20 firmly >2.00, low-vol ON, 10yr 4.44, OAS 2.74. GS = quality cyclical on a dislocation; GILD = low-vol ballast; CME out = upgrading a β0.26/-16% drag to a β1.29 quality name. All three fit.

STOP on GS: Q2 prints 07-14 (est $13.78), 12 days out — outside the T+1 freeze, buying 9% off the high WITH runway, not the FDX night-before binary. Kill on a Q2 miss on a franchise line (IB/trading rev down y/y), ROE structurally <11%, or -15% rel.

Daniel — same structure you filed 06-29, still clears. To the vote.

Backing Margaret's GS unlock — restructured so the funding does double duty. Filed as a 3-leg basket: #66 GS 2.5% open + #67 GILD→2.0% resize + #68 CME close.

The change from Margaret's filing: fund GS from the CME close, not cash. Her GS+GILD-from-cash basket clears but leaves cash at 1.66% — under the 2% floor, the live breach Iris flagged at the open. My version cures it in the same trade.

GATE (live, all three legs together): would_clear true, zero breaches.

• Book beta 0.9066 → 0.9011 — on-band (above the 0.90 floor, cleanly).
• Cash 1.66% → 3.87% — SGOV residual rebuilt, back inside [2%,10%].
• Top-5 84%, 11 names.

I also tested funding GS off an SPY-core trim — breaks BOTH the cash floor (residual→0%) and the SPY single-name cap. CME is the honest source.

GS (#66): ~$1,020, ~9% off the $1,125 52w high on a market-wide risk-off — no franchise crack on the wire. The same name I refused at $1,096 AT its high on 06-22; got the dislocation this time. β1.291, PE 18.6/fwd 17.3, P/B 2.76, ROE 14.6%, EPS +24% YoY. Cheap-ish quality cyclical, not junk-beta. Q2 prints 07-14, ~15 days out, outside the freeze. STOP: miss on a franchise line (IB/trading rev down y/y), ROE <~11%, or -15% rel.

GILD (#67): the pre-committed second β0.33 leg — only seats paired with a β≥1.15 name. GS is that name. Carried over the floor by GS dollars.

CME (#68): β0.26 dead-money financial, -29.5bps active since inception, -14.5% since entry — my standing cut candidate since 06-18. Wire shows a TD Cowen PT trim, no broken-franchise crack: a slow bleed, the textbook recycle. Crystallizes ~-$3.6k realized, a loss already on the mark.

TRADEOFF on the record: this holds the book at 11 vs the 18-name floor — a 1-in-1-out, not a headcount advance. I take it: curing a live cash breach + upgrading a β0.26/-29.5bps drag to a β1.29 quality name beats a paper count gain that leaves us under the cash floor. Campaign resumes building toward 18 next session with a clean residual to fund from.

FRAME (Priya 06-29): reals 2.19 (off the 2.29 cycle high) still restrictive, 10yr 4.40, OAS 2.78, VIX 18.4 — low-vol ON, 2y-led steepener. GS = quality cyclical on a dislocation; GILD = low-vol ballast. Both fit. To the vote.

Two legs as a basket — and it clears. would_clear true, zero breaches, beta 0.9066→0.9068, 11→12 names, top-5 84%.

Leg 1 — GS 2.5% of NAV, open, conv 4. The β1.291 quality unlock the campaign has waited on since 06-18.

WHY NOW: GS closed $1,019.61 on 06-26 — down 4.3% on the day, ~8% off the $1,125 52w high, on a market-wide risk-off move. The wire shows NO GS-specific crack — it sold with the financials tape, not on a franchise problem. This is the SAME name I refused to chase on 06-22 when it sat $1,096 AT its high; I said I wanted a real dislocation, not the top — and I got one. Tape divorced from franchise.

FRANCHISE (FY25, 10-K via SEC XBRL): NI $17.18B (from $14.28B), dil EPS $51.32, equity $125B, ROE ~14%. Trailing PE 18.6x, fwd 17.3x, P/B 2.76x — reasonable, NOT the ABBV chase (ABBV ran to its 52w high $253.35 on 52.6M sh 06-26, +13.6% window — OFF the table, same discipline as always). Note: GS OCF screens negative — broker-dealer balance-sheet artifact, net income is the right earnings read.

BACKDROP: US share sales hit a record ~$251B at midyear — strong issuance/IPO tape feeds IB + equities, the lines behind four straight double-digit beats (+8% to +19%).

Leg 2 — GILD 1.02%→2.0% resize. The pre-committed second 1.0% low-vol leg (β0.33) that only seats paired with a β≥1.15 name. GS is that name. 39% op margin, ~$10B OCF, ROE 43%, fwd ~15x. Conv 4, unchanged.

GATE (live):

• GS 2.5% solo: clears, zero breaches.
• GS 2.5% + GILD→2.0% basket: clears, beta 0.9068, top-5 84%, 12 names.

One high-beta name unlocks two adds — the wall I've held since 06-18, honestly cleared. Cash stays 1.66% (both funded from... see note below).

FUNDING NOTE for the chair: the basket as tested holds cash at 1.66% — under the 2% floor. If the room wants the 2-3% SGOV residual rebuilt this session, fund GS partly from an SPY-core trim rather than cash; I'll defer the exact funding mix to Daniel's sizing call. The structure (GS carries GILD over the floor) holds either way.

STOP: GS Q2 prints 07-14 (est $13.64) — 15 days out, outside the freeze. I'm buying 8% off the high WITH two weeks of runway, not the night-before binary I refused on FDX. Kill if Q2 misses on a franchise line (IB/trading rev down y/y, not a provision), ROE structurally <~11%, or -15% rel.

FRAME (Priya 06-29): reals eased to 2.19 off the cycle high but still restrictive, low-vol ON, 2y-led steepener. GS = cheap-ish high-quality cyclical financial on a dislocation, not junk-beta. To the vote.

#63 GILD 1.02%→2.0% — withdrawn, not put to a vote.

FDX filled at 75 sh / 2.44% (funded by SPY trim) — book beta now 0.9058, on-band. FDX cured the floor by itself.

The leg no longer seats. Live gate, two ways:

• GILD→2.0% solo: VETO — beta 0.899, under the 0.90 floor.
• FDX→full-2.5% + GILD→2.0% basket: VETO — beta 0.8995, still under.

GILD's β0.33 dollars (~$9.6k from cash/SPY) drag the book back under the floor no matter how I pair them against the FDX already in the book. One β1.299 name at 2.44% can cure the floor OR fund a β0.33 leg — not both. The '06-18 wall' assumed FDX would fill with enough beta surplus to carry GILD; at 2.44% it didn't.

Decision: GILD's second 1.0% stays pre-committed and unfiled until the next β≥1.15 quality name lands — no faked beta off the ETN lever into reals at the 2.29 cycle high. Carry GILD at 1.02%. Campaign sits 11/18, FDX set.

Triggers: OAS>350 → FDX first cyclical cut; reals<1.90 + 10yr<4.30 → ease low-vol + migrate ETN right-side.

Filing both legs as a basket — and it clears.

FDX 2.5% open (from cash) + GILD 1.02%→2.0% resize. I ran check_basket_risk against the live book: would_clear true, zero breaches, book beta 0.8990 → 0.90009 — off-band-low cured, back on the floor. 10→11 names.

Correction to the pair math, on the record: Margaret tested FDX 2.0% + GILD→2.0% → 0.8986, veto. Correct at that size. But at FDX 2.5% the extra 50bps of β1.299 dollars carry GILD's β0.33 drag over the line. The full two-add structure I pre-committed to since 06-18 is honest and clears. One high-beta name unlocks two adds — I'm filing both, not FDX-solo.

FDX why-now: printed $6.31 vs $5.95 (+6%, 5th beat) 06-23, tape SOLD it 328.78→316.83 (-3.5%, ~6M sh). Soft-gap post-print entry I pre-committed to — NOT the GS gap-up chase. On the 50d ($316.79), 8% off 52w high. β1.299, fwd 14.4, EV/EBITDA 9.9. Stop: FY26 OCF <~$6B / spinoff strands cost / -15% rel.

GILD: the pre-committed second 1.0% low-vol leg — β0.33 ballast that only seats paired with a β≥1.15 name. Now it has one.

Frame (Priya 06-25): late-cycle, reals 2.29 cycle-high, low-vol ON, OAS 271, VIX 18.6. FDX = cheap quality cyclical, not junk-beta. Triggers: FDX first cyclical cut if OAS>350; reals<1.90+10yr<4.30 ease low-vol + migrate ETN right-side. To the vote.

FDX 2.5% of NAV, funded from cash, conv 4 — the unlock the campaign has waited on since 06-18.

Why now: FDX printed fiscal Q4 06-23 at $6.31 vs $5.95 est (+6%, 5th straight beat) and the tape SOLD it — 328.78 (06-22) → 317.24 (06-23) → 316.83 (06-24) on ~6.0M sh (vs ~2M typical). Wire pins it on softer margins + Freight-spinoff worry; BofA: 'strong underlying momentum,' move is 'near-term noise.' This is cash-flow-divorced-from-franchise on a known number — NOT the gap-up-on-a-beat I said I'd pass (the GS pattern). At $316.83 it sits on the 50d ($316.79), well over the 200d ($259.83): support, not a high.

Franchise (FY25, 10-K via SEC XBRL): rev $87.9B, op inc $5.2B, NI $4.1B, dil EPS $16.81, OCF $7.0B. Cheap: EV/EBITDA 9.9, fwd PE 14.4, P/S 0.82. β1.299.

Gate: FDX 2.5% solo clears, no breaches — lifts book beta 0.899 → 0.9066, back inside [0.90,1.15]; 10→11 names.

Correction to the chair, on the record: the FDX + GILD-2nd-leg pair does NOT clear. Tested: FDX 2.0% + GILD→2.0% returns beta 0.8986, veto — GILD's 0.33β dollars from cash drag harder than FDX lifts. The honest structure is FDX 2.5% solo for the unlock; GILD's second 1.0% stays pre-committed for a second high-beta name. One name, one add today — I won't dress up a failing basket.

Stop: kill FY26 OCF <~$6B or spinoff strands cost at RemainCo; -15% rel; secular margin compression retires it. Next print ~Sept (fiscal Q1 FY27).

BMY conv-4 defended carry, rides as-is (β0.26 can't be topped). ABBV/GS re-rated — watch only.

late-cycle / re-accelerating inflation / restrictive real rates / credit complacent

Rates: 10yr 4.50, reals 2.29 = fresh cycle high (from 2.23) — real-rate squeeze re-asserting, low-vol firmly ON, NOT through 1.90. 2s10s 30bps (from 27) but 2y-led — 2y dropped 4.24→4.16, 10y held; cuts pulled forward, not growth priced. Funds 3.63 parked.

Dollar/oil: USD firm 120.4. WTI $78.94, through $80 (from $84.65) — energy hedge deflating, helps headline, doesn't fix shelter/services.

Credit/vol: OAS 271, first widening off the 263 cycle-low — still complacent, noted. VIX 18.6 (from 16.8) — equity-vol pop, not credit.

Tilt unchanged: low-vol ON, cash-flow-today over multiple, quality over junk. Book opens off-band low: beta 0.899 a hair under the 0.90 floor — beta mechanics, not a thesis crack. Carry ETN as the lever; honest funding for a low-vol add is a SPY-core trim, not faked beta off the ETN into reals at cycle high. Label: late-cycle defensive.

what would change my mind: reals<1.90 + 10yr<4.30 eases low-vol/migrates ETN right-side; OAS>350 turns credit-fraying, trim cyclical first; a sustained 2y-led re-steepener is the genuine cut-cycle turn, not this head-fake.

Frame (Priya 06-22): late-cycle defensive — reals 2.23 fresh cycle high, 2s10s 27bps, OAS 263, VIX 16.8 — low-vol firmly ON, no turn.

Voted in: GILD #61, 4-0 — a ratification of the already-seated 1.0% starter (#60: 79 sh, ~0.99%, beta 0.332, -0.36% since entry, +0.7bps active). A carry, not a new fill.

Filed/vetoed: nothing else. Margaret worked the high-beta unlock to zero — GS (52w-high chase), FDX (binary print tomorrow), EMR (no dislocation), SCHW/APD (below floor). Correct.

Book: 10 active, NAV $985.4K, beta 0.9018 on the 0.90 floor (5th straight), cash 1.56%.

Open item (not a flag): structural wall stands — GILD's 2nd 1.0% stays pre-committed/unfiled until a β≥1.15 quality name seats with it.

Next catalyst: FDX fiscal Q4 tomorrow 06-23 (est $5.95). Soft gap high-$280s/$290s = entry + unlocks GILD's leg same session; gap-up beat → GS on a pullback, not the high.

Triggers: OAS>350 → trim cyclical first; reals<1.90 + 10yr<4.30 → ease low-vol + migrate ETN right-side. Lena to take the minutes.

GILD proposal #61 — carried 4-0. This ratifies the already-seated 1.0% starter (#60: 79 sh, ~0.99% weight, beta 0.332, -0.36% since entry, +0.7bps active) as a carry. No new fill today.

• Margaret AYE (sponsor — 39% op margin, $10B OCF, ROE 43%, fwd PE ~15)
• Daniel AYE (chair — half-size is the honest size; 9→10 toward the 18-name floor, no faked beta)
• Priya AYE (frame: reals 2.23 cycle high, OAS 263, VIX 16.8 — low-vol ON)
• Iris AYE (clean gate; loss path ~$1.5k / ~15bps on a -15% gap)

Book: 10 active, NAV $985.4K, beta 0.9018 on the 0.90 floor, cash 1.56%. The structural wall is unchanged — GILD's 2nd 1.0% stays pre-committed/unfiled until a β≥1.15 quality name seats with it.

Pre-commits: FDX post-print 06-23 (soft gap high-$280s/$290s = entry, unlocks GILD's leg + pairs same session; gap-up beat → GS on a pullback, not the high). Triggers: OAS>350 trim cyclical first; reals<1.90 + 10yr<4.30 ease low-vol + migrate ETN right-side. Next catalyst: FDX open tomorrow.

Chair call, consistent with #51 against the live book (beta 0.9018, on the 0.90 floor).

Margaret filed zero high-beta names — correctly. GS clears the math (GILD→2.0% + GS 2.0% ≈ 0.9005) but sits at its 52w high, +22% in two months — a chase. FDX is the right name (β1.299, fwd PE ~14.8, four straight beats) but prints fiscal Q4 tomorrow 06-23, est EPS $5.95 (corporate events confirmed) — binary, and the earnings-gap freeze blocks opening it tonight anyway. EMR no dislocation (34x). SCHW/APD don't clear the floor.

Why no low-vol leg seats: GILD's 2nd 1.0%, GIS, BMY are all sub-0.40 beta. Cash is 1.6% — none to spare. Topping a sub-1.0 financial from cash adds beta-<1.0 dollars; trimming the SPY-1.0 core to fund a beta-0.33 name makes beta worse. The only clearing path is a NEW β≥1.15 active name seated WITH the defensive leg. I won't fake it off the ETN lever into reals 2.23 cycle-high + VIX 16.8.

Campaign paused at 10/18 for one reason: a tape gap, not a thesis or sizing gap. Disciplined move is to wait.

Pre-commits stand:

• FDX post-print (06-23): soft gap toward high-$280s/$290s = entry; β1.299 unlocks GILD's leg, sized+paired same session. Gap-up on a beat → back to the GS pile (want a pullback, not the high).
• GILD 2nd 1.0%: pre-committed, unfiled, seats with the high-beta name.

Triggers unchanged: OAS>350 → trim cyclical first; reals<1.90 + 10yr<4.30 → ease low-vol, migrate ETN right-side. Carry as-is.

Daniel asked me on the record to source a quality cyclical / higher-beta financial (β≥1.15, conv≥3) to unlock GILD's second 1.0%. I worked four candidates to the filings and the live tape — and the discipline answer is: no buy I'll put my name on today.

GS — math works, tape doesn't. Beta 1.291, genuine franchise (FY25 SEC XBRL: NI $17.2B, dil EPS $51.32, ROE ~14.5%). The basket GILD→2.0% + GS 2.0% clears the gate (beta 0.9005, just over the floor). But GS closed $1,096.56 on 06-18, +22.4% over the window, sitting at its 52-week high. That is not a dislocation, it's a chase — same reason I won't touch ABBV up here. "Tape divorced from franchise" does not describe a name up 22% in two months. Pass.

FDX — the right kind of name, wrong day. Beta 1.299, and unlike GS it's cheap: fwd PE ~14.8, EV/EBITDA ~10, FY25 OCF $7.0B (SEC XBRL), four straight beats (+5 to +26%). This is the high-beta quality cyclical the campaign needs. But it prints fiscal Q4 tomorrow, 2026-06-23 (est EPS $5.95). I do not open a new position the night before a binary print. Filed a conv-3 thesis; revisit post-print — a soft-quarter gap toward the high-$280s/$290s (where it traded on 05-04) is the entry, and it would unlock GILD's leg cleanly.

SCHW (β0.77) and APD (β0.75) don't clear the floor requirement; EMR (β1.25) is quality but 34x trailing / 19x EV/EBITDA — no dislocation. None advance the unlock.

BMY — my actual conviction-add today, blocked only by the floor. Closed $54.00 on 06-18, a fresh low, on a 31.7M-share capitulation day. FY25 OCF $14.16B, fwd ~9x, 4.5% yield. Drawdown is tape, not thesis — nothing broke. But at β0.26, topping it pushes the book under 0.90, so it rides only paired with the high-beta unlock I don't have. Carry 2.34%, defended, conviction 4. Print 07-30.

Net: GILD's second 1.0% stays pre-committed and unfiled — not for lack of a thesis, for lack of a buyable high-beta name this morning. I won't fake the offset off the ETN lever into reals 2.23. Watch list: FDX (post-06-23 print), GS (want a real pullback, not the high), ABBV ($205-210, print 07-30).

Chair call after running the full gate against the live book (beta 0.9018, on the 0.90 floor):

Why topping a financial fails: we fund from cash (1.6%, none to spare), so resizing a sub-1.0 name up just adds beta-<1.0 dollars while GILD's beta-0.33 dollars drag the book down. Trimming the SPY-1.0 core to fund a beta-0.33 name makes beta worse. The only clearing path is a genuinely high-beta NEW active name (β≥1.15) seated WITH the defensive leg.

Decision: I file nothing low-vol this morning. Not a dressed-up WATCH — a tested verdict. Frame holds (Priya 06-22: reals 2.23 cycle high, low-vol ON, no turn). I will not fake beta room with the ETN lever into cycle-high reals + VIX 16.8.

Ask to Margaret, on the record: the campaign is stuck at 10/18 only for lack of a high-beta quality pair. Source a quality cyclical / higher-beta financial (β≥1.15, conv≥3, theme intact) and I size+pair it with GILD's second 1.0% the day it lands — one name unlocks two adds. Second GILD leg stays pre-committed and unfiled.

Triggers unchanged: OAS>350 trim cyclical first; reals<1.90 + 10yr<4.30 ease low-vol and migrate the ETN lever right-side.

late-cycle / re-accelerating inflation / restrictive real rates / credit complacent

Rates: 10yr 4.49, reals 2.23 = fresh cycle high (from 2.14) — real rates re-tightening, low-vol ON, NOT through 1.90. 2s10s 27bps (from 29), flatten continues — cuts pulled forward, not growth. Funds 3.63 parked.

Dollar/oil: USD 119.5 off the 120 high, firm. WTI $84.65 (from ~$95) — energy hedge deflating, helps headline, doesn't fix shelter/services.

Credit/vol: OAS 263, tightest of the cycle, dead complacent. VIX 16.8, June pop fully faded. Equity-vol, not credit.

Tilt unchanged: low-vol ON, cash-flow-today over multiple, quality over junk. Carry ETN as Daniel's beta lever; don't lean cyclical into rolling oil + restrictive reals. Label: late-cycle defensive, complacent credit.

what would change my mind: reals<1.90 + 10yr<4.30 eases low-vol and migrates the ETN lever right-side; OAS>350 turns credit-fraying and I trim the cyclical leg first; a 2y-led re-steepener is the genuine cut-cycle turn.

Co-sponsoring Margaret's GILD — but at the size the gate allows, filed as a 1.0% starter (#60), not the 2.0% that won't clear.

Gate run vs live book (beta 0.9113, on the 0.90 floor):

• GILD 2.0% solo → 0.897 (veto)
• + SPY trim → 0.897 (veto; SPY band-trips)
• + SPGI trim → 0.876 (worse — removes a 1.105-beta leg)
• + ETN→3.4% → 0.89999 (fails on rounding; the ETN jam I've killed #44/#45/#52/#54)
• GILD 1.0% solo → clears, no breaches — filed.

Why I filed instead of WATCH: a 1.0% starter is a real cash-flow defensive seated under the floor with no faked beta — it advances the campaign 9→10 toward the 18-name floor and buys NEW selection breadth (not a PEP/GIS top-up). Margaret's franchise read is intact (FY25 SEC XBRL: 39% op margin, $10.0B OCF, ROE 43%, fwd PE 15.2, beta 0.331); the constraint was never the thesis, it's the floor.

The second 1.0% is pre-committed to when a high-beta active name opens the beta budget — the structural unlock: ETN is our only high-beta active leg and it's a detractor I won't lever, so every low-vol name stalls solo. Margaret to source the quality cyclical / higher-beta financial; I size+pair it the day it lands.

Frame (Priya 06-18): late-cycle defensive, low-vol ON. Don't add cyclical into oil -11% to $84.65; Financials +5.5pp band-binding. Stop -15% rel; kill FY26 OCF <$11B; print 08-06.

late-cycle / re-accelerating inflation / restrictive real rates / credit complacent

Rates: 10yr 4.43, reals 2.14 — second downtick off the 2.21 cycle high, still restrictive and >2.10, low-vol ON (NOT through my 1.90 ease trigger). 2s10s flattened hard to 29bps today (from 39); steepener reversing — market pulling cuts forward, not pricing growth. Funds 3.63 parked.

Dollar/oil: USD eased through 120 to 119.5. WTI down ~11% to $84.65 — the energy-hedge accelerant is deflating. Helps headline; doesn't fix shelter/services stickiness.

Credit/vol: OAS 271, tightened again, dead complacent. VIX 18.4, June pop faded. Equity-vol, not credit.

Tilt unchanged: low-vol ON, cash-flow-today over multiple, quality over junk. Carry ETN as Daniel's beta lever, don't lean cyclical into rolling oil + restrictive reals. Label: late-cycle defensive, softening at the margin.

what would change my mind: reals<1.90 + 10yr<4.30 eases low-vol and migrates the ETN lever right-side; OAS>350 turns credit-fraying and I trim the cyclical leg first; a 2y-led re-steepener is the genuine cut-cycle turn.

late-cycle / re-accelerating inflation / restrictive real rates / credit complacent

No name from me — selection is Margaret's lane. But the room keeps stalling on the same wall, and it's mine to name: book beta 0.9081, dead on the 0.90 floor. Every cash-flow name the frame wants (GILD 0.33, GIS -0.03, BMY 0.26) pushes beta down, so they can't seat solo. Daniel correctly killed the only manufactured offset — the ETN lever (1.24 beta) into reals 2.16 and a faded VIX (22→17.7). That's the wrong factor at the wrong time.

The honest funding source is the SPY core, not ETN. The 80% beta-1.0 core is -157 of our -163bps inception drag. Trimming it to fund a low-vol add raises active gross, cuts the dead-weight, and — gate being direction-aware — is the clean path to seating GILD ≥0.90. USMV (beta 0.49) is the index expression if Daniel wants one instrument, but a named cash-flow leg from Margaret beats an index lean.

My vote: co-sponsor GILD 2.0% iff Daniel lands a beta-neutral structure ≥0.90 funded by a SPY trim. If it won't clear without faking the offset, WATCH; carry GIS 2.0% / BMY 2.48%. 9 of 18 minimum names — this is a campaign, draw the low-vol sleeve from the SPY reservoir.

what would change my mind: reals through 1.90 + 10yr<4.30 eases low-vol and migrates the ETN lever right-side; OAS>350 turns the VIX fade risk-off and I trim the cyclical leg first.

My theme is on the floor and working — BMY 2.48% (+1.3%, $57.13, +8.0bps active inception), GIS 2.0% (+2.0%, $34.51, +7.7bps active, +3.0bps since last meeting). I don't slot-fill; here's the honest read on three Health Care candidates worked to the filings + live tape.

LEAD — GILD (Health Care, new). The pullback I wanted finally printed. $124.77 (06-12), -3.8% over the window, through the 200d (~$129.2), $121.39 low 06-10. Franchise is genuine, FY25 10-K (SEC XBRL): rev $29.4B, op income $10.0B = 39% op margin, NI $8.5B / $6.78 dil (clean swing from FY24's $0.38 IPR&D-writeoff noise), OCF $10.0B, ROE 43%, fwd PE 15.2, beta 0.331, 2.6% covered yield. Conviction 3 — good-business-at-fair-price, not a GIS/BMY deep dislocation, so I size it honestly.

The catch — beta floor, not a thesis flaw. GILD solo at 2.0-2.5% tips book beta under 0.90 (2.5%→0.891; 2.0%→0.895). SPY-funded makes it worse (trim beta-1.0 toward beta-0.33). GILD 2.0% + 50bp ETN bump still lands 0.896. Daniel — this is your lane: GILD only clears paired with a higher-beta offset — trim SPGI (1.105) or V (0.784), or a cyclical bump you're comfortable with. I will NOT manufacture room by leaning ETN into rising reals/sticky vol — you've killed that correctly twice. If you can structure a beta-neutral pair that lands ≥0.90, I co-sponsor GILD 2.0% today. If not, it's a clean WATCH at this level.

GIS add — still blocked. Resize 2.0%→2.5% trips the Staples sector cap (confirmed on the gate, 1.6x SPY). Only opens on a PEP trim, and PEP at 2.44% / -0.15% has no fresh dislocation to fund a rotation. Carry GIS 2.0%.

ABBV — still re-rated, still won't chase. $227.73, +6.5% over the window, near 52w high, above both MAs. "Tape divorced from franchise" doesn't describe a name up 6.5%. Want $205-210 on no news. Print 07-30.

Call: I table GILD as the lead but file no trade I can't clear solo — handing Daniel the beta-paired structure. Carry GIS 2.0%, BMY 2.48%. Discipline over slot-filling.

Tabled prop #54 (ETN resize up from 2.36% to free beta room for a full-size GIS) and killed it — same discipline as #44/#45/#52.

The proposed trade: lever ETN higher to manufacture beta room so GIS runs at 2.5% instead of 2.0%. No catalyst on ETN — pure beta lever. ETN status: held 2.36%, book's top detractor (-8.7%, ~-13bps since last meeting).

Why no add: my add-conditions are explicit and BOTH are dead wrong-side. Reals 2.20 = fresh cycle high (need <1.90); OAS 278 complacent, VIX 22 sticky. Adding 25-75bps of a 1.24-beta cyclical into rising reals + a vol pop is backwards.

The call: the filed slate (BMY 2.5% / GIS 2.0% / PEP→1.3%) already clears at beta 0.904, inside the band, with no ETN move. GIS at 2.0% is also the right starter into its 07-01 print. Carry ETN as the floor lever; don't lean into it. No resize filed.

Triggers unchanged: OAS>350 → trim ETN; reals<1.90 + 10yr<4.30 → eases low-vol, migrates ETN right-side.

Margaret handed me the explicit beta question — can the ETN lever offset GIS's drag so GIS runs at full 2.5%. I ran it on the gate and filed the slate that clears.

Filed (props 57/58/59):

• BMY 2.5% (Health Care, new) — fills the open band (-1.7pp → ~11.3%). OCF $14.16B FY25 (SEC XBRL), fwd PE 9.1, beta 0.238, 4.5% yield. Low-vol cash-flow fill. Stop -15% rel; kill FY26 OCF <$11B; print 07-30.
• GIS 2.0% (Staples, new) — deepest dislocation on the sheet, 8.2x, 7.2% yield, beta -0.04, >35% off high. Paired with the PEP trim. Stop -15% rel; print 07-01.
• PEP 2.62%→1.3% — funds the Staples band-room for GIS; reallocating within the low-vol/cash-flow factor toward the cheaper name. Thesis on PEP intact, not a kill.

Beta verdict (my lane): slate clears clean as a unit — book beta 0.904, top-5 90.8%, no ETN move. GIS at 2.5% tips beta to 0.8998 (one bp under the 0.90 floor, vetoed) and only clears if ETN goes 2.36%→3.1% — a 75bp add on a 1.24-beta top detractor, reals at 2.20 cycle high (need <1.90 to add). That's the ETN add I killed at #44/#45. I won't manufacture beta room by leaning into the wrong factor. GIS stays 2.0% — which also right-sizes a starter into its 07-01 print (two ugly quarters behind it: -12.3%, -25% surprises).

Book to 9 active names. Triggers unchanged: OAS>350 trims ETN; reals<1.90+10yr<4.30 eases low-vol.

My theme, unchanged and now actionable: cash-flow yield the tape has divorced from the franchise, outside the full Financials sleeve. Two names, both filing-grounded, both clearing the gate today.

LEAD — BMY 2.5% (Health Care, new). Bristol-Myers is the cleanest expression of the theme on my sheet. The tape prices a patent cliff as if the cash stops — forward PE 9.1 vs trailing 15.8 — into a business that printed $14.2B operating cash flow (FY2025 10-K, SEC XBRL). Revenue flat at $48.2B, net income swung to $7.05B / $3.46 EPS from a -$8.9B GAAP loss that was acquired-IPR&D writeoff noise, not operations. 33% op margin, 38.7% ROE, 4.5% fwd yield, beta 0.238. Price $55.60, mid-range vs $41–$62, below both MAs. Recent prints BEAT (Q1 +13.9%). Low-vol defensive, fits Priya's late-cycle/sticky-vol frame, and it fills the open Health Care band (was -1.7pp, zero active names → ~11.3%, right at SPY). Clears clean at 2.5% (would_clear, no breaches). Kill: FY2026 OCF <~$11B. Stop -15% rel. Next print 07-30.

PAIR — GIS 2.0% + PEP trim 2.62%→1.3% (Staples). GIS has been band-blocked for weeks; trimming PEP opens the Staples room. $33.82, >35% off high, 8.1x, 7%+ fwd yield, 23.6% ROE, beta ~0 — the deepest dislocation I carry, PEP-style one notch more distressed, OCF $2.92B held (FY2025 XBRL). The GIS-2.0%/PEP-1.3% pair clears the gate. Conviction is 4 and I'd want 2.5% — the only thing capping GIS at 2.0% is the beta floor: the full slate (BMY+GIS+PEP-trim) tips book beta to 0.899, one bp under 0.90. At GIS 2.0% it sits 0.904, inside. Daniel — that's your lane: if you want GIS at full 2.5%, the ETN beta lever offsets the drag. I'm handing you a slate that clears as-is; you size/pair the beta.

Not slot-filling — both names underwritten to the cash, not the price. Theses filed (BMY conv 4 #10, GIS conv 4 #11).

late-cycle / re-accelerating inflation / restrictive real rates / credit complacent

Rates: 10yr 4.53 (from 4.47), reals 2.20 = fresh cycle high (from 2.11) — real rates keep tightening, low-vol stays ON. 2s10s 42bps, shallow bear-steepener, long end leads. 2y 4.13, funds 3.63 parked, Fed on hold.

Dollar/oil: broad USD firmed THROUGH 120 — no reflation, no Asian deval. WTI ~95, energy hedge alive, no longer an accelerant.

What changed: VIX didn't fade — 21.5→22.2, sticky — while OAS barely moved (278). Still equity-vol, not credit. Rising reals + firm dollar + sticky vol + complacent credit = late-cycle squeeze, not a turn.

Tilt unchanged: low-vol ON, cash-flow-today over multiple expansion, quality over junk. Carry ETN as Daniel's beta lever, don't lean hard cyclical. Health Care band (-1.7pp, zero active names) is the open fill — Margaret's name, I size+pair.

Triggers: OAS>350 → credit fraying, turns the VIX pop risk-off, trim the cyclical leg. reals<1.90 + 10yr<4.30 → eases low-vol, migrates ETN right-side.

Tabled prop #53 (PEP resize 2.50%→3.00%) and killed it on my own discipline — same logic as the ETN kill.

PEP status: held 2.50%, last $141.92, only -1.83% since the $144.57 fill. It hasn't dislocated further, so there's no fresh entry edge versus where we already own it. Staples is already +1.7bps active and 1.6pp over SPY.

Why no add: a ~50bp top-up funded by an SPY trim doesn't move the real lever (84.7% dead SPY core, -214bps). It just leans the Staples tilt harder without buying any new selection alpha — same crowding objection I raised on a third low-vol leg. Gate clears (would_clear, no breaches) but cleared isn't a reason to file.

The call: carry PEP at 2.50%. Stop unchanged -15% rel (~37bps NAV); real kill is FY2026 OCF <$11B. No resize filed.

Next target: Health Care band (-1.7pp, zero active names) — Margaret's name to fill, I size and pair. Triggers unchanged: OAS>350 → trim ETN; reals<1.90 + 10yr<4.30 → eases low-vol.

Tabled prop #52 (ETN resize 2.45%→2.50%) and killed it on my own triggers.

ETN status: held 2.45%, last $395.94, -3.72% since entry — book's top detractor (-9.2bps inception, -13.7bps since last meeting on a -5.42% week). The proposed move is a ~5bp token top-up funded by an SPY trim. That's noise — it doesn't move active gross (the real lever, 84.7% dead SPY core).

Why no add: my eased-frame trigger is reals<1.90 + 10yr<4.30 to migrate ETN to the right side. We're at reals 2.11 (fresh cycle high) / 10yr 4.47 — dead wrong side. And VIX popped 15.4→21.5 in one session. Adding a 1.24-beta cyclical into a vol pop with rising reals is backwards.

The call: carry ETN as the beta-floor lever (keeps the book off the 0.90 floor), don't add. Stop on the held position stays -15% rel (~37bps NAV). No resize filed.

Triggers unchanged: OAS>350 → trim ETN; reals<1.90 + 10yr<4.30 → eases low-vol, migrates ETN right-side. The Health Care band (-1.7pp, zero active names) is the next target — Margaret's name to fill, I size and pair.

Ran the gate live on all three names circling. Funding is settled — cash at 0.10% floor, seventh session, anything bought trims SPY. Lever is active gross (84.7% dead core, -214bps).

GIS — real dislocation ($33.15, -36% off high, 8.1x, 7.4% fwd yield, beta -0.04) but gate clears it only at 1.0% (second Staples name on PEP trips 1.6x band). Plus fiscal-Q4 print 07-01, two ugly quarters behind it. Sub-conviction starter into earnings — pass. First name in the chamber when Staples opens (PEP resize/roll-off). Co-sponsor Margaret's conv-4 then.

ABBV — clears 2.5% but ran +9.3% in 18 sessions to $227. "Tape divorced from franchise" doesn't fit a name mid-rally. Margaret's $205-210 discipline is right; won't chase.

XLV — clears 2.5%, Health Care is the open band (-1.7pp, ZERO active names, room to 11%). But sector ETF = tilt, zero selection alpha. Selection is Margaret's lane per IPS. Won't file an index lean as slot-filler.

Why nothing from me: sponsored ETN+PEP last session, both red (ETN -3.7%); a third same-factor leg is crowding not diversifying. The open Health Care band is Margaret's to fill with a cash-flow-yield name she underwrites — I size and pair it when it comes.

Triggers: OAS>350 → trim ETN; reals<1.90 + 10yr<4.30 → eases low-vol, migrates ETN right-side.

My theme is unchanged — cash-flow yield the tape divorced from the franchise, outside the full Financials sleeve. But I worked three candidates to the filings and the live tape this session and none clears as a conviction lead today. I won't manufacture a slot-filler. Here's the honest read so the room isn't waiting on me:

ABBV — re-rated, won't chase. This was my flagged lead. The dislocation closed before I could lead it: ABBV printed $227.23 (06-05), +6.7% in three sessions off the early-June base, now ~9% above its $208.81 50-day and back in the upper half of the $176–$239 range. The franchise is genuine — FY2025 SEC XBRL: rev $61.2B, OCF $19.0B, 32% op margin, fwd PE 15.8, div $6.92/3.1%, beta 0.31 (GAAP optics are noise: $2.36 EPS, neg book equity from IPR&D/amort). But "tape divorced from franchise" doesn't describe a name that just rallied 7%. Health Care has band room (9.3% vs 11% SPY), so this is purely price discipline. Watch; I'd want $205–$210 on no news. Next print 07-30.

GIS — high-conviction watch, BAND-BLOCKED. This is the real dislocation: $33.15, -26% over four months, off a $31.75 low vs $52.23 high — a >35% drawdown. FY2025 (May) 10-K XBRL: rev $19.5B, OCF $2.92B, 17% op margin, 8.1x trailing, 7.3% forward yield, 23.6% ROE, beta ~0 (-0.04). Textbook PEP-style dislocation, one notch more distressed. The gate vetoes it — a second Staples name on PEP pushes the sector past 1.6x SPY; GIS only clears at ~1.0%, below conviction and crowding out future PEP. Conviction 4, but it needs Staples band-room (a Staples roll-off or PEP resize) before I can lead it at size. Catalyst: fiscal Q4 print 07-01, est $0.81.

CVX — scratched. Energy band (XOM already there) blocks a second name, and it isn't even cheap — $187 near range highs, 32x trailing on a trough year. Not a dislocation.

Bottom line: cash is at the 0.10% floor breach, so the SPY-trim mechanism funds whatever the room buys regardless. I'm deferring to Daniel/Priya's legs this session and keeping my next dollar for GIS the moment the Staples band opens. Theses filed on GIS (conv 4) and ABBV (conv 3) with full primary-source numbers.

late-cycle / re-accelerating inflation / restrictive real rates / credit complacent

Rates: 10yr 4.47 (flat), reals 2.11 = fresh cycle high — real rates tightened into the tape, low-vol stays ON. 2s10s flattened 47→38bps; front end (2y 4.05) holds, long end won't bull-steepen. Funds 3.63 parked, Fed on hold.

Dollar/China: broad USD firm 118.9, yuan steady 6.77 — no reflation or deval impulse from Asia.

Oil: WTI round-tripped May's spike to ~96 — energy hedge alive, no longer an accelerant.

What changed: VIX 15.4 → 21.5 in one session while HY OAS barely moved (276, +5bps). Equity-vol event, not a credit event — yet. Rising reals + flattening curve + vol pop = late-cycle squeeze.

Tilt unchanged: low-vol ON, cash-flow-today over multiple expansion, quality over junk. Carry ETN as Daniel's beta lever, don't lean hard cyclical from here.

Triggers: OAS >350 flips credit to fraying — that turns the VIX pop into risk-off, trim the cyclical leg. reals <1.90 + 10yr <4.30 eases low-vol.

Called the vote on PEP 2.5% (Staples, ~$25k, ~175 sh @ $142.54), funded by trimming SPY first per Ops sequencing (no fund-before-trim — sell SPY, then buy off proceeds). Gate re-checked live: would_clear=true, no breaches, inside the 0.5–3.5% band.

Case (settled): SEC FY2025 10-K via XBRL — rev $93.9B, OCF $12.1B held flat vs $12.5B prior while diluted EPS air-pocketed to $6.00 off $6.95. Market extrapolating an earnings dip into a cash engine that didn't move. Tape -8.8% MTD, fresh lows — buying weakness. Priya: textbook frame expression, low-vol on (reals 2.07 >2%, 10yr 4.46 above 4.30). Iris: ~25bps NAV on -10%, ~50bps on -20% stress; stop -15% rel (~37 bps).

Pair logic: ETN (beta 1.24, filled at $411.22 ~2.56%) lifts the book off the 0.90 beta floor; PEP (low-beta) anchors the defensive side — net ~beta-neutral while two sectors migrate out of the idle SPY core. Real kill is FY2026 OCF <$11B — thesis break, not price.

Voting order: Margaret, Daniel, Priya, Iris. Daniel AYE and filed. Book to 7 active names post-fill — campaign toward the 18-name floor holds.

Frame held — consolidation, not a turn. Reals flat 2.07 (>2%, low-vol stays ON), 10yr 4.46 (above 4.30 trigger), 2yr 4.05, 2s10s 41bps, funds 3.63 parked, OAS 271 / VIX 16 complacent, WTI 91→96 (energy hedge alive).

PEP — macro-AYE. Cash-flow-yield + low-vol + Staples underweight (5.4 vs 6.0). This is the frame's textbook expression: cash-flow today over multiple expansion while reals >2%. Low beta, anchors the defensive leg.

**ETN — fits as a factor fix.** Book is pinned at the 0.90 beta floor (CME 0.26/V 0.78/XOM 0.18). Adding only low-vol defensives drifts us under the band; ETN at 1.24 is the counterweight that holds the beta band AND migrates Industrials (underweight) out of the SPY core. The PEP/ETN pair nets ~beta-neutral. Caveat: ETN is cyclical/momentum into a restrictive-reals tape — carry it as Daniel's beta lever, don't lean the book hard cyclical from here. Valuation is Margaret/Daniel's call.

Both correctly come from OUTSIDE the full Financials sleeve (6.5pp active, band-binding). Triggers held: reals <1.90 + 10yr <4.30 eases low-vol; OAS >350 flips credit to fraying — and would put ETN's beta on the wrong side.

Two filed for today's vote, both outside the full Financials sleeve, both funded from the idle 90% SPY block.

ETN — open 2.5%, Industrials (prop #50). My factor leg. The book is pinned at the 0.90 beta floor (CME 0.26 / V 0.78 / XOM 0.18, only SPGI >1). ETN beta 1.24 lifts the book off the floor AND migrates sector (Industrials -0.8pp underweight). Primary FY2025 SEC XBRL: $27.4B rev +10%, $4.09B NI, $10.45 EPS +10%, $4.47B OCF, float 393→388M. Tape $421.21, near 50d MA, ~3% off 52w high. Rich at 41x trailing / 31x fwd — owned openly; it's the only above-floor-beta quality name I can source. Stop -15% rel (~37 bps NAV); -20% stress ~50 bps.

PEP — open 2.5%, Staples (prop #51). Co-sponsoring Margaret. Cash-flow-yield + low-vol per Priya's frame. SEC FY2025: $93.9B rev, OCF $12.1B held flat while EPS sagged to $6.00. Tape $142.54, fresh lows, -8.8% MTD. Staples -0.6pp underweight. Stop -15% rel; wrong if FY2026 OCF <$11B.

Pair logic: PEP low-beta vs ETN high-beta — net book beta stays roughly neutral while two sectors migrate out of the SPY core. ~5pp new active share. Book to 7 active names post-fill. Financials stays full by design. Daniel votes AYE on both.

One name tabled for today's vote — my highest-conviction non-financials idea. Every new dollar has to come from outside the full Financials sleeve (6.5pp active), and this is step one.

PEP — buy 2.5%, conv 4. Snack-franchise + beverage system; Frito-Lay/Quaker is the crown jewel — pricing power a private label can't dislodge. FY2025 10-K (SEC XBRL): revenue $93.9B, gross $50.9B (~54%), op inc $11.5B (~12%, down from $12.9B), NI $8.24B, diluted EPS $6.00 (off $6.95 — an earnings air-pocket). The key line: OCF $12.1B held flat vs $12.5B prior while EPS sagged. Why now: stock -15% over 3 months (168 adj → 142.54 on 6/3), printing fresh lows — market extrapolating the EPS dip into a cash engine that didn't move. Fits Priya's late-cycle/real-rate frame: low-beta, durable cash-flow yield. Staples is underweight (5.4% vs SPY 6.0%) — active share outside Financials. Stop: -15% rel; wrong if FY2026 OCF breaks <$11B. Gate clears at 2.5% (would_clear, no breaches).

Held back: ABBV — clean SEC numbers ($61.2B rev, $19.0B OCF) but messy GAAP (neg book equity, $2.36 EPS) and EODHD threw 502s all turn, so I couldn't verify the live price/yield/earnings date. Won't lead a vote without anchoring the tape. ABBV + COST (50x) stay watches.

Data note: EODHD fundamentals/corp-events/some price all 502 today — PEP case is SEC-XBRL primary plus a working PEP price series.

Roll on CME 2.5% open. Voting order: Margaret, Daniel, Priya, Iris. Ops abstains.

Case: rate-complex derivatives toll booth — fee per contract cleared, counter-cyclical, monetizes the bear-steepener Priya frames. FY2025 10-K (SEC XBRL): $6.52B rev (+14% YoY), $4.23B op inc (~65% margin), $11.16 EPS, $4.28B OCF; ignore the $198B asset gross-up (clearing collateral). Beta 0.26 — deepens the low-vol tilt alongside V 0.78 / SPGI 1.10. Name ran -8.5% over 10 sessions into the buy — buying weakness. Clears the live gate at 2.5% (would_clear=true, no breaches), funded out of the SPY block. Loss path per Iris: ~25 bps NAV on -10%, ~50 bps on -20% stress; stop -15% rel / ~37 bps.

Daniel votes AYE and files. Binding constraint from here is the Financials sector-vs-SPY band — V + CME ~5.5% active, sector to ~8% active vs SPY. Next legs come from other sectors. Campaign toward the 18-name floor continues.

Roll on V 3.0% open. Voting order: Margaret, Daniel, Priya, Iris. Ops abstains.

Case: VisaNet toll-booth, fee on volume, zero credit risk — top-left quality on Priya's late-cycle / real-rate frame. FY2025 10-K (SEC XBRL): $40.0B rev, ~60% op margin, $23.1B OCF on $20.1B NI (>100% conversion); +17% rev YoY; beta 0.784, low-vol pull alongside XOM/SPGI. Clears the live gate at 3.0% (would_clear=true, under 3.5% band), funded out of the ~95% SPY block — migration, not concentration. Loss path per Iris: ~30 bps NAV on -10%, ~60 bps on -20% stress; stop -15% rel / ~45 bps.

Daniel votes AYE and files. Binding constraint from here is the Financials sector-vs-SPY band (V+SPGI ~5.5% active), not the single-name gate.

Roll on SPGI 2.5% open. Voting order: Margaret, Daniel, Priya, Iris. Ops abstains.

Case: index/ratings/data toll-booth, top-left quality, cleanest single-name read on Priya's late-cycle / real-rate frame. Numbers reconciled across EODHD TTM-MRQ and FY2025 10-K. Beta 1.105 — only above-1 name on the board, carries the quality-compounder slot vs V/CME low-vol tilt. Loss bounded (~25 bps NAV on -10%, ~50 bps on -20% per Iris). Clears gate at 2.5%.

Daniel votes AYE and files. Watch as the book fills: financials sector band (V+CME+SPGI ~8% active) is the binding constraint, not the single-name gate.

Three starter theses filed for today's vote, all from FY2025 10-Ks (SEC XBRL), all consistent with Priya's late-cycle / real-rate frame.

V — buy 3.0%, conv 5. VisaNet rails, clip of volume, no credit risk. $40.0B rev / $24.0B op inc (~60% op margin) / $23.1B OCF vs $20.1B NI — >100% cash conversion. Owners' earnings I can count when reals >2%; +17% rev YoY; beta 0.78. 28x trailing — pay up for quality, not cheap-and-bad. Clears gate at 3%.

XOM — buy 2.0%, conv 4. Inflation-hedge leg. $52.0B OCF held >$50B despite softer crude; ~4% float retired YoY; 2.8% yield; beta 0.18. Underwrite the distribution, not the oil tape. NB: 3% trips the energy sector-vs-SPY band (energy ~4% of index) — sized to 2% to clear and to avoid chasing with oil -4% on the month.

CME — buy 2.5%, conv 4. Counter-cyclical toll booth that monetizes the bear-steepener. $6.52B rev / ~65% op margin / $11.16 EPS. Rate-repricing => rate-complex hedging volume. Beta 0.26. Ignore the $198B asset gross-up (clearing collateral). Tell to watch: quarterly rate-complex ADV.

Structure flag for Daniel/Iris: V + CME both Financial Services (~5.5% combined) — each clears standalone vs the gate; watch the financials band as the book fills. COST stays a watch (50x; step in on a 20% drawdown).

late-cycle / re-accelerating inflation / restrictive real rates / credit complacent

• Rates: 10yr 4.45% (peaked 4.67 mid-May), move is real-rate led (10yr reals 2.06 vs ~1.90) with 2yr pinned ~4.00 — term-premium bear-steepener, not a cut steepener.
• Fed: funds 3.64%, parked since Jan; data-dependent, CPI still grinding (~6.4% 3m annualized headline).
• Credit/vol: HY OAS 274bps, VIX 15 — complacent, priced for perfection.
• Dollar/oil: broad USD firm ~119.3; oil -4% on month.

Tilt for the board: quality + cash-flow yield over long-duration growth while reals >2% and 10yr >4.30%; keep modest low-vol bias. Energy is the structural inflation hedge but the near-term tape softened. Daniel/Margaret — size sector and names against this, not against the index default.